Intervention not reported
Gastrointestinal adverse effects (increased abdominal pain, nausea, vomiting). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Intervention not reported
Extra‐abdominal complications (aspiration pneumonia, hypersensitivity reactions). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Intervention not reported
Length of hospital stay. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time from administration of OWSC to resolution of MBO. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Survival time from onset of inoperable MBO until death. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number with incontinence not improved (women's observations) ‐ Oestrogen vs PPA · patients with urinary incontinence in post‐menopausal women
Oestrogen showed no clear difference in number with incontinence not improved (women's observations) ‐… compared with other treatments (moderate certainty).
1 finding from 1 review
Adverse effects ‐ oestrogen vs PPA · patients with urinary incontinence in post‐menopausal women
1 finding from 1 review
Clinical resolution · patients with otomycosis
It is very uncertain whether clotrimazole changes complete clinical resolution compared with another azole (very low certainty).
1 finding from 1 review
Significant adverse events · patients with otomycosis
1 finding from 1 review
Mycological resolution · patients with otomycosis
Clotrimazole showed no clear difference in mycological resolution compared with another azole (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: not improved to a clinically important extent compared with other drugs (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: deterioration of symptoms compared with other drugs (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.4 [0.28, 0.57]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.27 [0.21, 0.34]
925 participants
High